Stadler and Szmulewitz, therefore, advocate the use of sunitinib, despite the fact that this agent cures virtually no one, whereas high-dose IL-2 apparently cures about 8% of patients. High-dose ...
IL-8, IL-17 and IL-1 itself. The activity of IL-1β and IL-1α is controlled by IL-1RII, a decoy receptor, and IL-1Ra, a naturally expressed inhibitor of IL-1 receptor occupancy. As well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback